Ebola virus disease: An update on current prevention and management strategies

Journal of Clinical Virology

Volumn 86, Issue , 2017, Pages 5-13

  Trad, M A ^a,b,c   Naughton, W ^g   Yeung, A ^g   Mazlin, L ^d   O'sullivan, M ^i,j   Gilroy, N ⁱ   Fisher, D A ^e,f   Stuart, R L ^g,h  

^a WOLLONGONG HOSPITAL   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d MÉDECINS SANS FRONTIÈRES   (Belgium)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g SOUTHERN HEALTH   (Australia)

^h MONASH UNIVERSITY   (Australia)

ⁱ WESTMEAD HOSPITAL   (Australia)

^j University of Sydney   (Australia)

more..

Author keywords

Ebola; Ebolavirus; Management; Outbreak; Therapeutics; Vaccines

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; ANTIGEN; BLOOD DERIVATIVE; BRINCIDOFOVIR; EBOLA VACCINE; FAVIPIRAVIR; GALIDESIVIR; MB 003; MONOCLONAL ANTIBODY; MORPHOLINO OLIGONUCLEOTIDE; RECOMBINANT VACCINE; RECOMBINANT VESICULAR STOMATITIS VIRUS VECTOR VACCINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ZMAB; ZMAPP;

EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; FOLLOW UP; HUMAN; INFECTION PREVENTION; MENTAL HEALTH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; AFRICA; CLINICAL TRIAL (TOPIC);

AFRICA; CLINICAL TRIALS AS TOPIC; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84998992716     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2016.11.005     Document Type: Review

References (67)

1. [1] Bukreyev, A.A., Chandran, K., Dolnik, O., Dye, J.M., Ebihara, H., Leroy, E.M., et al. Discussions and decisions of the 2012–2014 international committee on the taxonomy of viruses (ICTV) filoviridae study group, January 2012–June 2013. Arch. Virol. 159:4 (2014), 821–830, 10.1007/s00705-013-1846-9.
2. [2] Feldmann, H., Geisbert, T.W., Ebola haemorrhagic fever. Lancet 377 (2011), 849–862.
3. [3] Baize, S., Pannetier, D., Oestereich, L., Reiger, T., Koivogui, L., Magassouba, N., et al. Emergence of zaire ebola virus disease in Guinea. N. Engl. J. Med. 371 (2014), 1418–1425.
4. [4] G.M. Lyon, A.K. Mehta, J.B. Varkey, K. Brantly, L. Plyler, A.K. McElroy, et al. Clinical Care of Two Patients with Ebola Virus Disease in the United States November 12, (epub ahead of print) 2014. doi: 10.1056/nejmoa1409838.
5. [5] http://www.cdc.gov/vhf/ebola/treatment/ Last accessed on 5/10/2016.
6. [6] Mohammadi, D., First trials for Ebola treatments announced. Lancet, 384(9957), 2014, 1833, 10.1016/S0140-6736(14)62043-2.
7. [7] Feldmann, H., Jones, S.M., Daddario-DiCaprio, K.M., Geisbert, J.B., Ströher, U., Grolla, A., Bray, M., et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog., 3(January (1)), 2007, e2.
8. [8] Choi, W.Y., Hong, K.J., Hong, J.E., Lee, W.J., Progress of vaccine and drug development for Ebola preparedness. Clin. Exp. Vaccine Res. 4 (2015), 11–16, 10.7774/cevr.2015.4.1.11.
9. [9] Marzi, A., Feldmann, H., Ebola virus vaccines: and overview of current approaches. Expert Rev. Vaccines 13:4 (2014), 521–531, 10.1586/14760584.2014.885841.
10. [10] Henao-Restrepo, A.M., Longini, I.M., Egger, M., Dean, N., Edmunds, W.J., Camacho, A., et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (2015), 857–866.
11. [11] Agnandji, S.T., Huttner, A., Zinser, M.E., Njuguna, P., Dahike, C., Fernandes, J.F., et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. NEJM 374 (2016), 1647–1660, 10.1056/NEJMoa1502924 (Epub 2015 April 1).
12. [12] Regules, J.A., Beigel, J.H., Paolino, K.M., Voell, J., Castellano, A.R., Munoz, P.et al., A recombinant vesicular stomatitis virus Ebola vaccine—preliminary report. NEJM(April), 2015.
13. [13] Mire, C., Matassov, D., Geisbert, J., Latham, T.E., Agans, K.N., Xu, R., et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature, 2015, 10.1038/nature14428.
14. [14] Wong, G., Richardson, J.S., Pillet, S., Patel, A., Qiu, X., Alimonti, J., et al. Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med., 4(158), 2012, 158ra146, 10.1126/scitranslmed.3004582.
15. [15] Mast, T.C., Klerstead, L., Gupta, S.B., Nikas, A.A., Kallas, E.G., Novitsky, V., et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralising antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28:4 (2010), 950–957, 10.1016/j.vaccine.2009.10.145.
16. [16] Zhu, F.C., Hou, L.H., Li, J.X., Wu, S.P., Liu, P., Zhang, G.R., et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet 385 (2015), 2272–2279, 10.1016/S0140-6736(15)60553-0 (Epub 2015 March 25).
17. [17] Steinbrook, R., One step forward, two steps back—will there ever be an AIDS vaccine. N. Engl. J. Med. 357 (2007), 2653–2655.
18. [18] Flamming, A., HIV vaccine failure due to induction of immune suppressors?. Nat. Rev. Drug Discov., 2014, 574–575, 10.1038/nrd4398.
19. [19] Kremer, E.J., Van de Perre, P., Ebola vaccines based on adenovirus vectors and risk of HIV. BMJ, 350, 2015, h1307.
20. [20] Lu, S., Wang, S., Grimmes-Serrano, J.M., Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines 7 (2008), 175–191.
21. [21] Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374:17 (2016), 1635–1646, 10.1056/NEJMoa1411627.
22. [22] Lai, L., Davey, R., Beck, A., Emergency postexposure vaccination with vesicular stomatitis virus-vectored ebola vaccine after needlestick. JAMA 313:12 (2015), 1249–1255, 10.1001/jama.2015.1995.
23. [23] Günther, S., Feldmann, H., Geisbert, T.W., Hensley, L.E., Rollin, P.E., Nichol, S.T., et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J. Infect. Dis. 204:Suppl. 3 (2011), S785–S790.
24. [24] Tsuda, Y., Parkins, C.J., Caposio, P., Feldmann, F., Botto, S., Ball, S., et al. A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose. Vaccine 33 (2015), 2261–2266, 10.1016/j.vaccine.2015.03.029.
25. [25] Jonsson-Scmunk, K., Croyle, M., A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact. Expert Rev. Anti Infect. Ther. 13:5 (2015), 527–530.
26. [26] Mupapa, K., Massamba, M., Kibadi, K., Kuvula, K., Bwaka, A., Kipasa, M., et al. Treatment: of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 179:Suppl. 1 (1999), S18–S23.
27. [27] Baron, R.C., Mc Cormick, J.B., Tubeir, O.A., Ebola virus disease in Southern Sudan: hospital dissemination and intrafamilial spread. Bull. World Health Organ. 61 (1983), 997–1003.
28. [28] Van Grienswen, J., Edwards, T., de Lamballerie, X., Semple, M.G., Gallian, P., Baize, S., et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374 (2016), 33–42, 10.1056/NEJMoa1511812.
29. [29] Luczkowiak, J., Arribas, J.R., Gomez, S., Jimenez-Yuste, V., de la Calle, F., Viejo, A., et al. Specific neutralizing response in plasma from convalescent petients of Ebola virus disease against the West Africa Makona variant of Ebola virus. Virus Res. 213 (2016), 224–229, 10.1016/j.virusres.2015.12.019.
30. [30] Pettitt, J., Zeitlin, L., Kim do, H., Working, C., Johnson, J.C., Bohorov, O., et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med., 5, 2013, 199ra113, 10.1126/scitranslmed.3006608.
31. [31] Qiu, X., Audet, J., Wong, G., Pillet, S., Bello, A., Cabral, T., et al. Successful treatment: of ebola virus–infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med., 2012, 1138ra81, 10.1126/scitranslmed.3003876.
32. [32] Qiu, X., Wong, G., Fernando, L., Audet, J., Bello, A., Strong, J., et al. MAbs and ad-vectored IFN-a therapy rescue ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci. Transl. Med., 5, 2013, 207ra143, 10.1126/scitranslmed.3006605.
33. [33] Dowall, S.D., Graham, V.A., Corbin-Lickfett, K., Empig, C., Schlunegger, K., Bruce, C.B., et al. Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions. J. Immunol. Res., 2015, 9, 10.1155/2015/347903 (Article ID 347903).
34. [34] Oestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., Günther, S., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 105 (2014), 17–21.
35. [35] Sissoko, D., Laouenan, C., Folkesson, E., M'Lebing, A.-B., Beavogui, A.-H., Baize, S., et al. Experimental treatment: with favipiravir for ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med., 13(3), 2016, e1001967, 10.1371/journal.pmed.1001967.
36. [36] Bouazza, N., Treluyer, J.-M., Foissac, F., Mentré, F., Taburet, A.-M., Guedj, J., et al. Favipiravir for children with Ebola. Lancet 385 (2015), 603–604, 10.1016/s0140-6736(15)60232-x.
37. [37] Geisbert, T.W., Lee, A.C., Robbins, M., Geisbert, J.B., Honko, A.N., Sood, V., et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375 (2010), 1896–1905.
38. [38] Warren, T.K., Warfield, K.L., Wells, J., Swenson, D.L., Donner, K.S., Van Tongeren, S.A., et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 16:September (9) (2010), 991–994, 10.1038/nm.2202.
39. [39] Florescu, D.F., Keck, M.A., Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses. Expert Rev. Anti Infect. Ther. 12:October (10) (2014), 1171–1178, 10.1586/14787210.2014.948847.
40. [40] Warren, T.K., Wells, J., Panchal, R.G., Stuthman, K.S., Garza, N.L., Van Togeren, S.A., et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508 (2014), 402–405.
41. [41] Florescu, D.F., Kalil, A.C., Hewlett, A.L., Schuh, A.J., Stroher, U., Uyeki, T.M., et al. Administration of Brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin. Infect. Dis. 61:6 (2015), 969–973, 10.1093/cid/civ395.
42. [42] Wolf, T., Kann, G., Becker, S., Stephan, C., Brodt, H.R., de Leuw, P., et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet(December), 2014, 62384–62389, 10.1016/s0140-6736(14)62384-9 pii: S0140-6736(14)62384.
43. [45] Lópaz, M.A., Amela, C., Ordobas, M., Domínguez-Berjón, M.F., Álvarez, C., Martínez, M., et al. First secondary case of Ebola outside Africa: epidemiological characteristics and contact monitoring, Spain,S eptember to November 2014. Euro Surveill., 20(1), 2015 pii=21003.
44. [46] Sullivan, N.J., Geisbert, T.W., Geisbert, J.B., Xu, L., Yang, Z., Roederer, M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424 (2003), 681–684.
45. [47] Stanley, D.A., Honko, A.N., Asiedu, C., Trefry, J.C., Lau-Kilby, A.W., Johnson, J.C., et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20:October (10) (2014), 1126–1129, 10.1038/nm.3702.
46. [48] N. Thomas, Novavax Study to evaluate the immunogenicity and safety of an Ebola virus glycoprotein vaccine in healthy subjects. In: ClinicalTrials.gov [internet] Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 Jun 8]. Available from: http://clinicaltrials.gov/show/NCT02370589. NLM Study identifier: NCT02370589.
47. [49] Dye, J.M., Herbert, A.S., Kuehne, A.I., Barth, J.F., Muhammad, M.A., Zak, S.E., et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. PNAS 109:13 (2012), 5034–5039, 10.1073/pnas.1200409109.
48. [50] Olinger, G.G. Jr., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 109:October (44) (2012), 18030–18035, 10.1073/pnas.1213709109.
49. [51] Liberia-U.S. Clinical Research Partnership Opens Trial to Test Ebola Treatments http://www.niaid.nih.gov/news/newsreleases/2015/Pages/ZMapp.aspx (accessed 27.02.15).
50. [52] Shedlock, D.J., Bailey, M.A., Popernack, P.M., Cunningham, J.M., Burton, D.R., Sullivan, N.J., Antibody mediated neutralization of ebola virus can occur by 2 distinct mechanisms. Virology 401:2 (2010), 228–235, 10.1016/j.virol.2010.02.029.
51. [53] http://hfv.lanl.gov/content/sequence/HFV/ToolsOutline.html (accessed 04.03.16).
52. [54] Gignoux, E., Azman, A.S., de Smet, M., Azuma, P., Massaquoi, M., Job, D., et al. Effects of Artesunate-Amodiaquine on mortality related to Ebola virus disease. N. Engl. J. Med. 374:1 (2016), 23–32, 10.1056/NEJMoa1504605.
53. [55] Cooper, B.S., Boni, M.F., Pan-ngum, W., Day, N.P.J., Horby, P.W., Olliaro, P., et al. Evaluating clinical trial designs for investigational treatments of ebola virus disease. PLoS Med., 12(4), 2015, e1001815, 10.1371/journal.pmed.1001815.
54. [56] Petrosillo, N., Nicastri, E., Lanini, S., Capobianchi, M.R., Di Caro, A., Antonini, M., et al. Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infect. Dis., 15, 2015, 432, 10.1186/s12879-015-1169.
55. [57] Shurtleff, A.C., Whitehouse, C.A., Ward, M.D., Cazares, L.H., Bavari, S., Pre-symptomatic diagnosis and treatment of filovirus diseases. Front Microbiol., 6(108), 2015, 10.3389/fmicb.2015.00108 (Published onlineFebruary 20).
56. [58] Kraft, C.S., Hewlett, A.L., Koepsell, S., Winkler, A.M., Kratichvil, C.J., Larson, L., et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin. Infect. Dis. 61:4 (2015), 496–502, 10.1093/cid/civ334.
57. [59] Wong, K., Perdue, C., Malia, J., Kenney, J.L., Peng, S., Gwathney, J.K., et al. Supportive care of the first 2 Ebola virus disease patients at the monrovia medical unit. Clin. Infect. Dis. 61:7 (2015), e47–e51, 10.1093/cid/civ420 (first ublished online May 28, 2015).
58. [60] O'shea, M.K., Clay, K.A., Craig, D.G., Moore, A.J., Lewis, S., Espina, M., et al. Case report a health care worker with Ebola virus disease and adverse prognostic factors treated in Sierra Leone. Am. J. Trop. Med. Hyg., 2016, 10.4269/ajtmh.15-0461 (Published online February 22, 2016).
59. [61] Cotte, J., Cordier, P.Y., Bordes, J., Janvier, F., Esnault, P., Kaiser, E., et al. Fluid resuscitation in Ebola Virus Disease: a comparison of peripheral and central venous accesses. Anaesth. Crit. Care Pain Med. 34:December (6) (2015), 317–320, 10.1016/j.accpm.2015.06.010 (Epub 2015 Nov 2).
60. [62] Evans, D.K., Goldstein, M., Popova, A., Health-care worker mortality and the legacy of the Ebola epidemic. Lancet Global Health 3:8 (2015), e439–40, 10.1016/S2214-109X(15)00065-0.
61. [63] http://www.nbcdfw.com/news/health/Ebola-Patient-Dr-Kent-Brantly-to-Leave-Hospital-Thursday-272102161.html (Last accessed 06.07.16).
62. [64] Tiffany, A., Vetter, P., Mattia, J., Dayer, J.A., Bartsch, M., Kasztura, M., et al. Ebola virus disease complications as experienced by survivors in Sierra Leone. Clin. Infect. Dis., 21, 2016, 10.1093/cid/ciw158 (first published online March).
63. [65] Sow, M.S., Etard, J.F., Baize, S., Magassouba, N., Faye, O., Msellati, P., et al. New evidence of long-lasting persistence of Ebola virus genetic material in semen of survivors. J. Infect. Dis.(May), 2016 (Pii:jiw078. [Epub ahead of print]).
64. [66] www.who.int/csr/research-and-development/blueprint/en (Last accessed on 03.10.16).
65. [67] www.who.int/csr/resources/publications/ebola/report-by-panel.pdf?ua=1 (Last accessed 03.10.16).
66. [68] Davidson, E., Bryan, C., Fong, R.H., Barnes, T., Pfaff, J.M., Rucker, J.B., et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol. 89:21 (2015), 10982–10992, 10.1128/JVI.01490-15.
67. [69] Baranovskiy, A.G., Babayeva, N.D., Suwa, Y., Gu, J., Pavlov, Y.I., Tahirov, T.H., Structural basis for inhibition of DNA replication by aphidicolin. Nucleic Acids Res. 42:December (22) (2014), 14013–14021.